Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.

The time-dependent covariate for grade greater than or equal to 2 pneumonitis or RT-pneumonitis was not a significant factor for PFS and TTDM in either model (nominal p > 0.1) but was nominally significant for OS in both models (patients with grade ≥2 pneumonitis or RT-pneumonitis had an increased risk of death at any given time versus those without the event); however, the benefit of durvalumab versus placebo was unchanged when the time-dependent covariate was incorporated into the OS models.

also in 7,732 other papers